GlassScriptPhysician profile
Azka Tasleem
NPI 1134780703
$579.29
in general payments reported to CMS, 2019-2025
10 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.29 · 2023: $197 · 2024: $169 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.00 |
| Education | $114.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $147.78 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $123.94 | 2024-2025 | Jakafi, Monjuvi |
| Novartis Pharmaceuticals Corporation | $85.51 | 2025 | |
| Asd Specialty Healthcare, LLC | $48.47 | 2023 | |
| Pfizer INC. | $41.65 | 2023-2024 | |
| Exelixis INC. | $33.82 | 2024-2025 | Cabometyx |
| Abbvie INC. | $28.55 | 2023 | Venclexta |
| Astellas Pharma US INC | $27.56 | 2023 | Cresemba |
| Astrazeneca Pharmaceuticals LP | $23.11 | 2023 | |
| Janssen Biotech, INC. | $18.90 | 2025 | Rybrevant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azka Tasleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.